KalVista appoints Laurence Reid, Ph.D. to Board of Directors

KalVista Pharmaceuticals, Inc.

Laurence Reid appointed to KalVista Board effective Nov 23, 2024; term expires at 2027 annual meeting.
Compensation: initial option for 17,000 shares, $42,500 annual cash retainer, annual option for 10,000 shares.
Reid brings over 30 years biotech experience; was CEO of Decibel Therapeutics prior to Regeneron acquisition.
Reid's appointment comes as KalVista progresses sebetralstat toward FDA PDUFA date of June 17, 2025.
Board determined Reid independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.